Summary : Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the…
Vaccine
-
-
RegulatoryU.S FDA
GC Pharma Receives Complete Response Letter From the U.S. FDA For ‘ALYGLO’
by adminby adminSummary : GC Pharma (KRX:006280) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug…
-
Covid DrugsGskSanofi Inc.
Data delivery: Sanofi and GSK seek authorisation for COVID-19 vaccine
by adminby adminSynopsis : Pharma giants take major stride as vaccine shows significant increase in neutralising antibodies Sanofi and GlaxoSmithKline (GSK) have announced that…
-
Summary : The Committee for Medicinal Products for Human Use (CHMP) has provided an initial assessment of Valneva’s inactivated, adjuvanted COVID-19 vaccine…
-
AstraZenecaCovid DrugsRegulatoryU.S FDA
FDA Adjusts EUA Dosing On Evusheld To Fight Omicron
by adminby adminSummary: The U.S. Food and Drug Administration (FDA) has revised its emergency use authorization (EUA) for AstraZeneca’s Evusheld to a higher dose…
-
Global MarketGsk
Medicago’s Plant-Based Vaccine Bolstered by GSK Adjuvant Wins First Approval
by adminby adminSummary : Canada’s Medicago scored a regulatory first after Health Canada approved its plant-based COVID-19 vaccine Covifenz that has been paired with…
-
Covid DrugsWHO
EU countries agree to admit travellers vaccinated with WHO-approved Covid shots
by adminby adminSummary : European Union countries agreed on Tuesday to open their borders to travellers from outside the bloc who have had shots…
-
Covid DrugsPharma Science & Research
World’s First Monoclonal Antibody Prequalifies To Treat COVID
by adminby adminSynopsis: In order to increase access to treatments that are recommended to fight COVID-19, the WHO has added a monoclonal antibody treatment…
-
Although fractures normally heal, bone will not regenerate under several circumstances. When bone does not regenerate, major clinical problems could result, including…
-
Summary : The U.S. Food and Drug Administration has accepted Mirati Therapeutics’ New Drug Application (NDA) for its candidate drug for non-small cell lung cancer (NSCLC). The…